Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 19;25(2):1266.
doi: 10.3390/ijms25021266.

Role of Immunotherapy in Sarcomas

Shivani Dalal  1 , Khine Swe Shan  1 , Nyein Nyein Thaw Dar  1 , Atif Hussein  1 , Alejandra Ergle  1
Affiliations
Review

Role of Immunotherapy in Sarcomas

Shivani Dalal et al. Int J Mol Sci. .

Abstract

Sarcomas are a group of malignancies of mesenchymal origin with a plethora of subtypes. Given the sheer heterogeneity of various subtypes and the rarity of the disease, the management of sarcomas has been challenging, with poor patient outcomes. Surgery, radiation therapy and chemotherapy have remained the backbone of treatment in patients with sarcoma. The introduction of immunotherapy has revolutionized the treatment of various solid and hematological malignancies. In this review, we discuss the basics of immunotherapy and the immune microenvironment in sarcomas; various modalities of immunotherapy, like immune checkpoint blockade, oncolytic viruses, cancer-targeted antibodies, vaccine therapy; and adoptive cell therapies like CAR T-cell therapy, T-cell therapy, and TCR therapy.

Keywords: CAR T-cell therapy; TCR therapy; adoptive cell therapy; immune microenvironment; immunotherapy; oncolytic viruses; sarcomas.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
CAR T-cell-Leukapheresis, T-cell modification, expansion, and CAR T-cell infusion.
Figure 2
Figure 2
CAR T-cell structure.
Figure 3
Figure 3
TCR.
Figure 4
Figure 4
Oncolytic Viruses.
Figure 5
Figure 5
Cancer Vaccines.
See this image and copyright information in PMC

References

    1. Banks L.B., D’Angelo S.P. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook. J. Natl. Compr. Cancer Netw. 2022;20:834–844. doi: 10.6004/jnccn.2022.7027. - DOI - PubMed
    1. Sbaraglia M., Bellan E., Dei Tos A.P. The 2020 WHO Classification of Soft Tissue Tumours: News and perspectives. Pathol. J. Ital. Soc. Anat. Pathol. Diagn. Cytopathol. 2020;113:70–84. doi: 10.32074/1591-951X-213. - DOI - PMC - PubMed
    1. Savina M., Le Cesne A., Blay J.Y., Ray-Coquard I., Mir O., Toulmonde M., Cousin S., Terrier P., Ranchere-Vince D., Meeus P., et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: The METASARC observational study. BMC Med. 2017;15:78. doi: 10.1186/s12916-017-0831-7. - DOI - PMC - PubMed
    1. Von Mehren M., Kane J.M., Agulnik M., Bui M.M., Carr-Ascher J., Choy E., Connelly M., Dry S., Ganjoo K.N., Gonzalez R.J., et al. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2022;20:815–833. doi: 10.6004/jnccn.2022.0035. - DOI - PMC - PubMed
    1. Penel N., Bui B.N., Bay J.-O., Cupissol D., Ray-Coquard I., Piperno-Neumann S., Kerbrat P., Fournier C., Taieb S., Jimenez M., et al. Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study. J. Clin. Oncol. 2008;26:5269–5274. doi: 10.1200/JCO.2008.17.3146. - DOI - PubMed